Geisinger Health System
Exome Sequencing for Cerebral Palsy Has Sufficient Diagnostic Yield for First-Tier Test
A meta-analysis of prior studies found that the diagnostic yield of exome sequencing for cerebral palsy exceeded 31 percent, similar to other neurodevelopmental disorders.
Survey Suggests Polygenic Embryo Screening Has Higher Public Acceptance Than Anticipated
A national survey of more than 6,800 US participants asked about attitudes towards polygenic embryo screening, germline genome editing, and SAT prep courses.
While Geisinger sees value in identifying at-risk patients and diagnosing cancer early, some experts are concerned about overtreatment.
Geisinger MyCode Study Reveals Prevalence of Somatic Variants Linked to Rare Syndrome
Using exome sequence data for more than 163,000 Geisinger MyCode participants, researchers looked for variants in UBA1 that have been linked to VEXAS syndrome.
Freenome Partners With Geisinger to Recruit Patients for Multi-Cancer Screening Study
The Pennsylvania health system will be able to access patients in both urban and rural settings, aiding Freenome's goal to recruit a total of 8,000 individuals.